Ambrx tries another IPO as it chases down HER2 rivalsCalifornia biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Share XAmbrx tries another IPO as it chases down HER2 rivalshttps://pharmaphorum.com/news/ambrx-tries-another-ipo-as-it-chases-down-her2-rivals/
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancersWith an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now Share XASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancershttps://pharmaphorum.com/news/asco-2020-astrazeneca-enhertu-cancer/
FDA sets August action date for Seattle’s oral HER2 drug tucatinibSeattle Genetics is a few months away from having its third drug product on the market, after the Share XFDA sets August action date for Seattle’s oral HER2 drug tucatinibhttps://pharmaphorum.com/news/fda-sets-august-action-date-for-seattles-oral-her2-drug-tucatinib/
Exclusive Pfizer Speaker Interview ReleasedExclusive Pfizer Speaker Interview Released Share XExclusive Pfizer Speaker Interview Releasedhttps://pharmaphorum.com/partner-content-oncology/exclusive-pfizer-speaker-interview-released/
